GERN Stock Analysis: Buy, Sell, or Hold?
GERN - Geron Corp
$1.41
0.01 (0.71%)
▲
5d:
-8.44%
30d:
-16.07%
90d:
+2.92%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
GERN is down 4.1% this week, but smart money is accumulating calls. Top strike: $2 2026-06-18 with 3,608 OI. Call ratio: 100% View Scanner →
Strength: 7.1/10
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GERN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GERN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.41, which is considered oversold relative to its 30-day fair value range of $1.46 to $1.74. The stock's valuation (Forward PE: 17.6) is in line with its historical norms (19.5). Remarkably, the market is currently pricing in an annual earnings decline of 3.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GERN is showing support break momentum. The price is currently testing key support at $1.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GERN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.40 (+141.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GERN is showing support break momentum. The price is currently testing key support at $1.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GERN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.40 (+141.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.46 -
$1.74
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding GERN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 141.1% below Wall St target ($3.40)
- CAUTION: 5-day price weakness (-8.4%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$1.46 -
$1.74
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.38
Resistance Level
$1.70
Current Trend
Support Break
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.62
Wall Street Target
$3.40
(+141.1%)
Revenue Growth (YoY)
1.0%
Profit Margin
-45.4%
Valuation Discount vs History
-3.4% cheaper
PE vs Historical
17.6 vs 19.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.4%
(market-implied from PE analysis)
1-Year Target
$1.36
(-3%)
2-Year Target
$1.32
(-7%)
3-Year Target
$1.27
(-10%)
3-Yr Target (if PE normalizes)
(PE: 18→20)
$1.41
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.6 to 19.5
Stabilization Target:
$1.56
(+10.6%)
PE Expansion Potential:
+10.6%
Share & Embed Analysis
Last updated: March 30, 2026 6:31 PM ET
Data refreshes hourly during market hours. Next update: 7:31 PM
Data refreshes hourly during market hours. Next update: 7:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$134 | 59 HOLD |
|
EXEL
Exelixis Inc |
BUY
20 analysts |
$47 | 62 BUY |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
